The CSM(B) stated that "the perceived level of risk" did not justify a "serious consideration" of withdrawing USA products from the UK Market. In addition it was not feasible on the grounds of supply.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Professor Arthur L Bloom
Dr John D Craske
Dr Nicol Spence Galbraith
Dr Harold H Gunson
Dr Philip Mortimer